FDA speeds up review of Roche's Tecentriq to treat another bladder cancer

ZURICH (Reuters) - Roche said on Monday that U.S. regulators agreed to priority review of its Tecentriq immunotherapy for an additional type of bladder cancer, a boost to the Swiss drugmaker's bid to expand indications for the drug.